Kishore, Asha
Sturm, Marc http://orcid.org/0000-0002-6552-8362
Soman Pillai, Kanchana
Hakkaart, Christopher
Kalikavil Puthanveedu, Divya
Urulangodi, Madhusoodanan http://orcid.org/0000-0002-1536-3686
Krishnan, Syam http://orcid.org/0000-0002-2889-2771
Ashok Kumar Sreelatha, Ashwin
Rajan, Roopa
Pal, Pramod Kumar
Yadav, Ravi
Sarma, Gangadhara
Casadei, Nicolas http://orcid.org/0000-0003-2209-0580
Gasser, Thomas http://orcid.org/0000-0002-1069-1146
Bauer, Peter
Riess, Olaf
Sharma, Manu http://orcid.org/0000-0002-1260-5416
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research
Deutsche Forschungsgemeinschaft
Article History
Received: 25 May 2023
Accepted: 29 February 2024
First Online: 15 April 2024
Competing interests
: Financial disclosures of all authors (for the preceding 12 months). A.K. discloses nothing to report. M.S. discloses nothing to report. K.S.P. discloses nothing to report. C.H. discloses nothing to report. D.K.P. discloses nothing to report. M.U. discloses nothing to report. S.K. discloses nothing to report. A.A.S. discloses nothing to report. R.R. discloses nothing to report. P.K.P. has received grants (funded to his Institute) for research projects as Principal or Co-Investigator from the Indian Council of Medical Research (ICMR), Department of Biotechnology (DBT), Department of Science & Technology (DST)-Science and Engineering Research Board, DST-Cognitive Science Research Initiative, Wellcome Trust UK-India Alliance DBT, PACE scheme of BIRAC, and Michael J. Fox Foundation, and funding (to his Institute) as a Co-Investigator for a clinical trial from ERYDEL SpA, Italy Europe. Also received honoraria as Faculty/Speaker/Author from the International Parkinson and Movement Disorder Society, and Movement Disorder Societies of Korea, Taiwan, and Bangladesh. R.Y. discloses nothing to report. G.S. discloses nothing to report. N.C. discloses nothing to report. T.G. Stock Ownership in medically related fields—NONE—Intellectual Property Rights—patent: KASPP (LRRK2) gene, its production, and its use for the detection and treatment of neurodegenerative disorders. Patent Number: EP1802749 (A2). Consultancies—Royalties for consulting activities from Cefalon Pharma and Merck-Serono—Expert Testimony—NONE. Advisory Boards—Editorial board member of Parkinsonism and Related Disorders, Journal of Parkinson’s Disease, Neurogenetics; Scientific advisory board, Joint Programming in Neurodegenerative Diseases; Advisory board, UKDP—Employment—Center for Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen and German Center of Neurodegenerative Diseases (DZNE), Tübingen. Partnerships—NONE—Contracts—NONE. Honoraria—Speaker’s honoraria from Novartis, Merck-Serono, Schwarz Pharma, Boehringer Ingelheim and Teva Pharma—Royalties—NONE. Grants—Novartis Pharma, the Federal Ministry of Education and Research (BMBF), the Helmholtz Association, the European Commission, the German Research Foundation, and the Michael J. Fox Foundation. Other—NONE. P.B. discloses nothing to report. O.R. discloses nothing to report. M.S. discloses nothing to report.